Skip to main content

Table 3 Comparison between group I (control group) and group II (case group) regarding levels of hemoglobin, AST, ALT, albumin, total bilirubin, INR, platelets, and creatinine before start of treatment

From: Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study

  Group I Group II Test value p value
Hemoglobin (gm/dl) Mean ± SD 14.56 ± 1.72 12.09 ± 1.75 7.111 0.001
Range 10.8–17.6 10–16.4
AST (U/L) Normal 31 (62.0%) 37 (74%) 1.654 0.198
High 19 (38.0%) 13 (26%)
ALT (U/L) Normal 31 (62%) 35 (70%) 0.407 0.523
High 19 (38%) 15 (30%)
Albumin (gm/dl) Mean ± SD 4.28 ± 0.41 4.03 ± 0.37 3.253 0.002
Range 2.6–5 3.1–5.1
Bilirubin (mg/dl) Mean ± SD 0.65 ± 0.24 0.58 ± 0.19 1.610 0.111
Range 0.2–1.4 0.19–1
INR Mean ± SD 1.09 ± 0.09 1.12 ± 0.11 − 1.675 0.097
Range 0.9–1.3 0.89–1.4
Platelets (103/mm3) Mean ± SD 233.88 ± 67.28 215.18 ± 67.56 1.387 0.169
Range 94–400 108–372
Creatinine (mg/dl) Median (IQR) 0.85 (0.8–0.91) 7.3 (6.1–9.49) − 8.631 0.001
Range 0.5–1.3 3.6–12.75